- Home
- GF vs ALDX Comparison
GF vs ALDX Comparison
Compare GF & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GF
- ALDX
- Stock Information
- Founded
- GF 1990
- ALDX 2004
- Country
- GF Germany
- ALDX United States
- Employees
- GF N/A
- ALDX N/A
- Industry
- GF Investment Managers
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- GF Finance
- ALDX Health Care
- Exchange
- GF Nasdaq
- ALDX Nasdaq
- Market Cap
- GF 155.4M
- ALDX 160.8M
- IPO Year
- GF N/A
- ALDX 2014
- Fundamental
- Price
- GF $12.33
- ALDX $4.76
- Analyst Decision
- GF
- ALDX Strong Buy
- Analyst Count
- GF 0
- ALDX 2
- Target Price
- GF N/A
- ALDX $9.50
- AVG Volume (30 Days)
- GF 28.1K
- ALDX 1.2M
- Earning Date
- GF 01-01-0001
- ALDX 07-31-2025
- Dividend Yield
- GF 0.82%
- ALDX N/A
- EPS Growth
- GF N/A
- ALDX N/A
- EPS
- GF N/A
- ALDX N/A
- Revenue
- GF N/A
- ALDX N/A
- Revenue This Year
- GF N/A
- ALDX N/A
- Revenue Next Year
- GF N/A
- ALDX N/A
- P/E Ratio
- GF N/A
- ALDX N/A
- Revenue Growth
- GF N/A
- ALDX N/A
- 52 Week Low
- GF $7.38
- ALDX $1.14
- 52 Week High
- GF $9.41
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- GF 70.86
- ALDX 78.74
- Support Level
- GF $11.84
- ALDX $4.12
- Resistance Level
- GF $12.47
- ALDX $4.60
- Average True Range (ATR)
- GF 0.15
- ALDX 0.29
- MACD
- GF 0.04
- ALDX 0.08
- Stochastic Oscillator
- GF 89.08
- ALDX 90.91
About GF New Germany Fund Inc. (The)
NEW GERMANY FUND INC is a non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investment includes investments in different sectors such as the industrials, information technology, material, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.